Comparative study of efficacy and safety of omega 3 fatty acids and fenofibrate with background atorvastatin therapy in patients of atherogenic dyslipidaemia

Simple item page
dc.contributor.authorArora, Ankiten_US
dc.contributor.authorSingh, Navyug Rajen_US
dc.contributor.authorSharma, Rajiven_US
dc.date.accessioned2020-04-23T07:56:23Z
dc.date.available2020-04-23T07:56:23Z
dc.date.issued2019-06
dc.description.abstractBackground: Trials of atorvastatin combined either with fenofibrate or with omega-3 fatty acids (O3FA) have shown promising results in atherogenic dyslipidemia but there are very few studies where both these TGs lowering agents have been compared with each other. This study was conducted to compare efficacy and safety of these two agents on lipid profile of patients of atherogenic dyslipidaemia on background statin therapy and also to monitor effects of these interventions on serum uric acid (SUA) levels.Methods: About 90 patients of dyslipidemia were randomised to 3 groups and received O3FA (2000 mg), fenofibrate (80 mg) or dietary restrictions, each with atorvastatin (20 mg) in background for a period of 90 days. Total cholesterol (TC), HDL-C,TGs, LDL-C, SGOT and SGPT levels were done at baseline, 6 weeks and 12 weeks. Other parameters (SUA and BMI) were done at baseline and 12 weeks.Results: Both group 1 (O3FA) and group 2 (fenofibrate) showed highly significant fall in TG levels (p <0.001) in comparison to group 3 (dietary restrictions) whereas comparative TG reduction between groups 1 and group 2 was not significant. Group 2 also showed significant fall in LDL-C levels (p <0.01) in comparison to group 3. LDL-C reduction, TG reduction and SUA reduction was more in group 2 compared to group 1 followed by group 3. No significant difference was observed in the incidence of adverse effects in three study groups.Conclusions: Combination of fenofibrate and atorvastatin was more effective than that of omega-3 fatty acid and atorvastatin, in lowering serum TG and LDL-C levels. There was a significant reduction in SUA levels in all three groups, but combination of fenofibrate and atorvastatin again showed better outcomes. With respect to the safety, all the 3 groups were comparable. O3FA, however, may be a good alternative to fibrates in patients not tolerating latter.en_US
dc.identifier.affiliationsDepartment of Pharmacology, Government Medical College, Amritsar, Punjab, Indiaen_US
dc.identifier.affiliationsDepartment of Internal Medicine, Lifecare Hospital, Amritsar, Punjab, Indiaen_US
dc.identifier.citationArora Ankit, Singh Navyug Raj, Sharma Rajiv. Comparative study of efficacy and safety of omega 3 fatty acids and fenofibrate with background atorvastatin therapy in patients of atherogenic dyslipidaemia. International Journal of Basic & Clinical Pharmacology. 2019 Jun; 8(6): 1145-1152en_US
dc.identifier.issn2319-2003
dc.identifier.issn2279-0780
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/200197
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber6en_US
dc.relation.volume8en_US
dc.source.urihttps://dx.doi.org/10.18203/2319-2003.ijbcp20192176en_US
dc.subjectAtherogenic dyslipidaemiaen_US
dc.subjectAtorvastatinen_US
dc.subjectFenofibrateen_US
dc.subjectHypertriglyceridemiaen_US
dc.subjectOmega-3 fatty acidsen_US
dc.titleComparative study of efficacy and safety of omega 3 fatty acids and fenofibrate with background atorvastatin therapy in patients of atherogenic dyslipidaemiaen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijbcp2019v8n6p1145.pdf
Size:
304.46 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Basic & Clinical Pharmacology